Hongyuan Pharmaceutical: Announcement on the proposal of the company and its subsidiaries to apply for comprehensive credit lines from financial institutions and provide guarantees for subsidiaries in 2026
Securities code: 301246 Securities abbreviation: Hongyuan Pharmaceutical Announcement number: 2026-012
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
Regarding the company and its subsidiaries’ application for comprehensive insurance from financial institutions in 2026
Announcement on credit lines and provision of guarantees for subsidiaries
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete, and there are no false records, misleading statements or major omissions.
Hubei Hongyuan Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company" or "Hongyuan Pharmaceutical") held the 15th meeting of the fourth board of directors on April 27, 2026, and reviewed and approved the "Proposal on the Company and its Subsidiaries to Apply for Comprehensive Credit Lines from Financial Institutions in 2026 and Provide Guarantees for Subsidiaries". The relevant information is hereby announced as follows:
- Application for a comprehensive credit line from a financial institution and provision of guarantee for a subsidiary’s comprehensive credit
(1) Application for comprehensive credit limit
According to the 2026 production and operation plan and fund use plan of the company and its wholly-owned subsidiaries, it plans to apply to financial institutions for no more than RMB 175,000. A comprehensive credit line of RMB 10,000. The above-mentioned comprehensive credit includes but is not limited to working capital loans, project loans, fixed asset loans, M&A loans, bank acceptance bills, bill pool business, letter of guarantee, factoring, issuance of letters of credit, bills, trade financing, bill discounting, financial leasing and other businesses. The above credit line is not equal to the company's actual financing amount. The specific cooperative financial institutions and the final financing amount and form will be further negotiated with the relevant financial institutions to determine, and shall be subject to the officially signed agreement.
In order to meet the operational development needs of the wholly-owned subsidiaries and wholly-owned subsidiary companies, the total amount of guarantees (including bank loan guarantees and other external financing guarantees) planned to be provided to the wholly-owned subsidiaries Wuxue Hongyuan Pharmaceutical Co., Ltd., Hubei Tongdetang Pharmaceutical Co., Ltd., Wuhan Shuanglong Pharmaceutical Co., Ltd. and the wholly-owned subsidiary Hubei Hongyuan Fluorochemical Co., Ltd. in 2026 shall not exceed RMB 670 million.
In order to handle the application for the comprehensive credit line of the above-mentioned financial institution and subsequent related borrowings, guarantees and other matters, the company intends to authorize the chairman of the company or other authorized persons to handle relevant procedures on behalf of the company within the above-mentioned limit, and sign all contracts, agreements, vouchers and other legal documents related to comprehensive credit within the above-mentioned limit.
The company and its wholly-owned subsidiaries' application for a comprehensive credit line from a financial institution in 2026 and the provision of a guarantee line for the subsidiary will be valid for twelve months from the date of review and approval by the board of directors. The comprehensive credit line and guarantee line can be recycled during the validity period.
The specific financing amount under the above credit line will ultimately be subject to the actual needs of the company, each wholly-owned subsidiary and wholly-owned subsidiary company, as well as the actual approval of banks and other financial institutions.
(2) Estimated guarantee limit for comprehensive credit in 2026
Unit: Guarantee limit of RMB 10,000
secured party
As of 2026, the share of listed companies is
Guaranteed party’s shareholding Latest issue
Guaranteed Party Secured Party Previous Guarantee Estimated New Increment Company’s latest related ratio Assets and liabilities
Balance Guarantee Amount Net Assets for the Period Guarantee Ratio
Proportion
Hubei Province Macro
Source Fluorine Chemical
Company 100.00% 91.16% 0 65,000 14.58% No limited liability
company
Wuxue Hongyuan
Company Pharmaceutical Co., Ltd. 100.00% 99.09% 29,000 1,000 0.22% No company
Hubei Tongde
Company Tang Pharmaceutical has 100.00% 140.40% 0 500 0.11% No limited company
Wuhan Double Dragon
Company Pharmaceutical Co., Ltd. 100.00% 82.14% 0 500 0.11% No company
Total 29,000 67,000 15.03%
Note: The above guarantee amount will ultimately be subject to the needs of each wholly-owned subsidiary and wholly-owned subsidiary company, as well as the actual approval of financial institutions such as banks and the aforementioned contract. The amount of guarantee provided by the approved company to the above-mentioned wholly-owned subsidiaries and wholly-owned subsidiary companies can be adjusted internally according to the actual situation of the above-mentioned subsidiaries.
2. Basic information of the guaranteed person
(1) Hubei Hongyuan Fluorine Chemical Co., Ltd.
Date of establishment: March 18, 2021
Registered address: Phase III of Makou Pharmaceutical and Chemical Park, Tianzhen, Wuxue City, Huanggang City, Hubei Province
Type: Limited liability company (a sole proprietorship of a legal person that is not invested or controlled by a natural person)
Legal representative: Deng Zhihua
Registered capital: RMB 10 million
Business scope: General projects: manufacturing of basic chemical raw materials (excluding the manufacture of hazardous chemicals and other licensed chemicals); manufacturing of special chemical products (excluding hazardous chemicals); production of chemical products (excluding licensed chemical products); manufacturing of electronic special materials; processing of renewable resources; technical consultation on resource recycling services; technical services, technology development, technical consultation, technology exchange, technology transfer, and technology promotion (in addition to licensed business, projects that are not prohibited or restricted by laws and regulations can be independently operated in accordance with the law)
Equity structure: Wuxue Hongyuan Pharmaceutical Co., Ltd. holds 100% of the shares, and the company indirectly holds 100% of the shares.
Main financial data: After audit, as of December 31, 2025, total assets were 254.6393 million yuan and net assets were 22.4987 million yuan. In 2025, the operating income will be 147,500 yuan and the net profit will be -1.5633 million yuan.
(2) Wuxue Hongyuan Pharmaceutical Co., Ltd.
Date of establishment: October 14, 2019
Registered address: No. 10, Jianshe Avenue, Makou Chemical Industrial Park, Wuxue City, Huanggang City, Hubei Province
Type: Limited liability company (a sole proprietorship of a legal person that is not invested or controlled by a natural person)
Legal representative: Deng Zhihua
Registered capital: RMB 60 million
Business scope: Licensed items: pharmaceutical production; pharmaceutical commissioned production; pharmaceutical import and export; inspection and testing services. (Projects that require approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to approval documents or licenses from relevant departments.) General projects: production of chemical products (excluding licensed chemical products); sales of chemical products (excluding licensed chemical products); manufacturing of basic chemical raw materials (excluding manufacturing of licensed chemicals such as hazardous chemicals); import and export of goods; manufacturing of special electronic materials; sales of special electronic materials; technical services, technology development, technical consultation, technical exchanges, technology transfer, and technology promotion. (Except for licensed business, you can independently operate projects that are not prohibited or restricted by laws and regulations in accordance with the law)
Equity structure: The company holds 100% of the shares
Main financial data: After audit, as of December 31, 2025, total assets were 1,328,749,100 yuan and net assets were 12,146,500 yuan. In 2025, operating income was 41.7481 million yuan and net profit was -41.6645 million yuan.
(3) Hubei Tongdetang Pharmaceutical Co., Ltd.
Date of establishment: December 24, 2004
Registered address: No. 9, Fengshan Avenue, Economic Development Zone, Luotian County, Huanggang City, Hubei Province
Type: Limited liability company (a sole proprietorship of a legal person invested or controlled by a natural person)
Legal representative: Liao Shengru
Registered capital: RMB 10 million
Business scope: Licensed projects: pharmaceutical production; disinfectant production (excluding hazardous chemicals); Class II medical device production; medical mask production; sanitary products and disposable medical supplies production; medical staff protective equipment production (Class II medical devices ); Drug production (excluding the application of processing technologies such as steaming, frying, roasting, and forging of traditional Chinese medicine pieces and the production of confidential prescription products for proprietary Chinese medicines); pharmaceutical production (excluding the application of processing technologies such as steaming, frying, roasting, and forging of traditional Chinese medicine pieces and confidential prescriptions of proprietary Chinese medicines) Production of products); import and export of medicines; decoction services of traditional Chinese medicine slices; food production; food sales; health food production (projects that are subject to approval according to law can only be carried out with the approval of relevant departments. Specific business projects are subject to approval documents or licenses from relevant departments) General projects: entrusted production of medicines; production of traditional Chinese medicine extracts; health food (pre-packaged) sales (except for licensed businesses, projects that are not prohibited or restricted by laws and regulations can be independently operated in accordance with the law) Equity structure: The company holds 100% of the shares
Main financial data: After audit, as of December 31, 2025, total assets were 80.5262 million yuan and net assets were -32.5314 million yuan. In 2025, operating income was 49.7778 million yuan and net profit was -3.8612 million yuan.
(4) Wuhan Shuanglong Pharmaceutical Co., Ltd.
Date of establishment: March 4, 2003
Registered address: No. 9, Yousha Road, Wujiashan Taiwanese Investment Zone, Wuhan City
Type: Limited liability company (a sole proprietorship of a legal person invested or controlled by a natural person)
Legal representative: Feng Bin
Registered capital: RMB 60 million
Business scope: Licensed projects: pharmaceutical production; pharmaceutical wholesale; pharmaceutical import and export; food sales (projects that require approval according to law can only be carried out after approval by relevant departments. Specific business projects are subject to the approval documents or licenses of relevant departments) General projects: Sales of Class I medical devices sales; sales of Class II medical devices; sales of disinfectants (excluding hazardous chemicals); wholesale of cosmetics; sales of health food (prepackaged); research and development of machinery and equipment; sales of food (only sales of prepackaged food) (except for projects that require approval according to law, business activities can be carried out independently with a business license in accordance with the law)
Equity structure: The company holds 100% of the shares
Main financial data: After audit, as of December 31, 2025, total assets were 43.2891 million yuan and net assets were 7.7303 million yuan. In 2025, operating income was 25.1844 million yuan and net profit was -2.3641 million yuan.
After inquiry, it was found that the above-mentioned guaranteed subsidiary was not a defaulter.
3. Main contents of the guarantee agreement
This time, the guarantee provided for the subsidiary's application for credit from financial institutions is a joint liability guarantee. The amount and period of each guarantee are determined according to the contract signed after final negotiation between the subsidiary and the relevant financial institution. The final total actual guarantee amount shall not exceed the reviewed guarantee limit.
4. Relevant review and approval procedures
(1) Review status of the board of directors
On April 27, 2026, the company held the 15th meeting of the fourth board of directors and reviewed and approved the "Proposal on the Company and its Subsidiaries to Apply for Comprehensive Credit Lines from Financial Institutions in 2026 and Provide Guarantees for Subsidiaries." After review, the board of directors believes that the financial risks of the company and its subsidiaries applying for a comprehensive credit line from financial institutions and providing guarantees for subsidiaries in 2026 are within the company's controllable range and are in compliance with relevant documents of the China Securities Regulatory Commission, Shenzhen Stock Exchange and the provisions of the Articles of Association.
5. Cumulative number of external guarantees and number of overdue guarantees
As of the disclosure date of this announcement, the balance of external guarantees provided by the company and its subsidiaries is 290 million yuan, accounting for 6.50% of the company's latest audited net assets. Combined with the guarantee limit approved this time, the cumulative total guarantees of the company and its subsidiaries will be 960 million yuan, accounting for 21.53% of the company's latest audited net assets. The company and its subsidiaries do not provide guarantees to companies outside the scope of the consolidated statements, there are no overdue guarantees, there are no guarantees involved in litigation, and there are no guarantees that should bear losses due to a judgment against the guarantee.
6. Documents for reference
- Resolution of the 15th meeting of the 4th Board of Directors.
Announcement is hereby made.
Board of Directors of Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
April 29, 2026